QuidelOrtho Reagents and Supplies Standing Order – FY 2027

The NIH Clinical Center’s Transfusion Services Laboratory requires a FY 2027 standing order for QuidelOrtho blood‑bank reagents, gel cards, antisera, quality‑control kits, reagent red blood cells, diluents, and associated supplies to support 24/7 patient and donor testing. The government intends to source exclusively from QuidelOrtho Sales Company, LLC, citing their unique proprietary reagents and the lack of authorized third‑party distributors. Interested vendors may submit a capability statement demonstrating ability to provide the required products and documentation of authorization to supply QuidelOrtho items. The contract period runs from October 1 2026 through September 30 2027, with deliveries scheduled throughout the year to meet short‑shelf‑life requirements. • Supplies are critical for safe blood transfusion and must match existing validated testing protocols. • Only QuidelOrtho is deemed capable; however, capability statements are accepted to evaluate potential competition. • Responses are due by October 5 2026, 1 PM ET, and will be used to determine if a competitive procurement is warranted.